Inositol monophosphatase (IMPase) is an enzyme with two homologs-IMPA1 and IMPA2-that is responsible for dephosphorylating myo-inositol monophosphate to generate myo-inositol. IMPase has been extensively studied in neuropsychiatric diseases and is regarded as a susceptibility gene. Recently, emerging evidence has implied that IMPase is linked to cancer development and progression and correlates with patient survival outcomes. Interestingly, whether it acts as a tumor-promoter or tumor-suppressor is inconsistent among different research studies. In this review, we summarize the latest findings on IMPase in cancer, focusing on exploring the underlying mechanisms for its pro- and anticancer roles. In addition, we discuss the potential methods of IMPase regulation in cancer cells and the possible approaches for IMPase intervention in clinical practice. Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Qian Chen, Liangfang Shen, Shan Li. Emerging role of inositol monophosphatase in cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 May;161:114442
PMID: 36841024
View Full Text